Exact Mass: 285.046
Exact Mass Matches: 285.046
Found 336 metabolites which its exact mass value is equals to given mass value 285.046,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
5-Amino-4-chloro-2-(5-hydroxymuconoyl)-3(2H)-pyridazinone
Fludarabine
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D000970 - Antineoplastic Agents Fludarabine (NSC 118218) is a DNA synthesis inhibitor and a fluorinated purine analogue with antineoplastic activity in lymphoproliferative malignancies. Fludarabine inhibits the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in normal resting or activated lymphocytes[1][2][3][4].
Cladribine
Cladribine is only found in individuals that have used or taken this drug. It is an antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. [PubChem]Cladribine is structurally related to fludarabine and pentostatin but has a different mechanism of action. Although the exact mechanism of action has not been fully determined, evidence shows that cladribine is phosphorylated by deoxycytidine kinase to the nucleotidecladribine triphosphate (CdATP; 2-chloro-2′-deoxyadenosine 5′-triphosphate), which accumulates and is incorporated into DNA in cells such as lymphocytes that contain high levels of deoxycytidine kinase and low levels of deoxynucleotidase, resulting in DNA strand breakage and inhibition of DNA synthesis and repair. High levels of CdATP also appear to inhibit ribonucleotide reductase, which leads to an imbalance in triphosphorylated deoxynucleotide (dNTP) pools and subsequent DNA strand breaks, inhibition of DNA synthesis and repair, nicotinamide adenine dinucleotide (NAD) and ATP depletion, and cell death. Unlike other antimetabolite drugs, cladribine has cytotoxic effects on resting as well as proliferating lymphocytes. However, it does cause cells to accumulate at the G1/S phase junction, suggesting that cytotoxicity is associated with events critical to cell entry into S phase. It also binds purine nucleoside phosphorylase (PNP), however no relationship between this binding and a mechanism of action has been established. L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D000970 - Antineoplastic Agents Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis[1][2].
7-Aminoclonazepam
7-aminoclonazepam belongs to the family of Benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms).
Faropenem
Faropenem is an orally active beta-lactam antibiotic belonging to the penem group. It is resistant to some forms of extended-spectrum beta-lactamase. It is available for oral use. Faropenem was developed by Daiichi Asubio Pharma, which markets it in two forms. The sodium salt faropenem sodium, available under the trade name Farom, has been marketed in Japan since 1997. (CID 636379 from PubChem) The prodrug form faropenem medoxomil (also known as faropenem daloxate) has been licensed from Daiichi Asubio Pharma by Replidyne, which plans to market it in conjunction with Forest Pharmaceuticals. The trade name proposed for the product was Orapem, but company officials recently announced this name was rejected by the FDA.
Asenapine
2,5-Dioxopyrrolidin-1-yl quinolin-6-ylcarbamate
D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents
5-(4-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole
9-Chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine
4-(2-Methoxyphenyl)-2-((5-methyl-1H-imidazol-4-yl)methyl)thiazole
Nifuratel
2-Chloro-9-(2-deoxy-beta-D-arabinofuranosyl)adenine
3H-1,4-Benzodiazepin-2-amine, 7-chloro-5-phenyl-, 4-oxide
Theasaponin E3
Theasaponin e3 is a member of the class of compounds known as quinazolines. Quinazolines are compounds containing a quinazoline moiety, which is made up of two fused six-member aromatic rings, a benzene ring and a pyrimidine ring. Theasaponin e3 is practically insoluble (in water) and a very weakly acidic compound (based on its pKa). Theasaponin e3 can be found in tea, which makes theasaponin e3 a potential biomarker for the consumption of this food product.
1-(3,4-dichlorophenyl)-6,6-dimethyl-1,3,5-triazine-2,4-diamine
O1-(3-amino-phenyl)-beta-D-glucopyranuronic acid|O1-(3-Amino-phenyl)-beta-D-glucopyranuronsaeure
3,3-dimethyl-4-oxo-5-[(S)-3,3,3-trichloro-2-methylpropyl]-2-pyrrolidinone
Cladribine
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01B - Antimetabolites > L01BB - Purine analogues C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents C471 - Enzyme Inhibitor > C2157 - Adenosine Deaminase Inhibitor C274 - Antineoplastic Agent > C798 - Radiosensitizing Agent D000970 - Antineoplastic Agents CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2617; ORIGINAL_PRECURSOR_SCAN_NO 2616 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2634; ORIGINAL_PRECURSOR_SCAN_NO 2632 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2626; ORIGINAL_PRECURSOR_SCAN_NO 2625 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2623; ORIGINAL_PRECURSOR_SCAN_NO 2621 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2643; ORIGINAL_PRECURSOR_SCAN_NO 2642 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 2641; ORIGINAL_PRECURSOR_SCAN_NO 2639 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5653; ORIGINAL_PRECURSOR_SCAN_NO 5650 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5671; ORIGINAL_PRECURSOR_SCAN_NO 5668 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5700; ORIGINAL_PRECURSOR_SCAN_NO 5699 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5680; ORIGINAL_PRECURSOR_SCAN_NO 5677 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5706; ORIGINAL_PRECURSOR_SCAN_NO 5702 CONFIDENCE standard compound; INTERNAL_ID 1343; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 5693; ORIGINAL_PRECURSOR_SCAN_NO 5691 Cladribine (2-Chloro-2′-deoxyadenosine), a purine nucleoside analog, is an orally active adenosine deaminase inhibitor. Cladribine functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. Cladribine can inhibit DNA methylation. Cladribine has anti-lymphoma activity. Cladribine can be used for the research of several hematologic malignancies and multiple sclerosis[1][2].
4-HYDROXY-1-[(4-METHYLPHENYL)SULFONYL]-2-PYRROLIDINECARBOXYLIC ACID
3-AMINO-7-CHLORO-5-PHENYL-1,3-DIHYDRO-BENZO[E][1,4]DIAZEPIN-2-ONE
(2-Methyl-5-(morpholinosulfonyl)phenyl)boronic acid
flunoxaprofen
M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids > M01AE - Propionic acid derivatives G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CC - Antiinflammatory products for vaginal administration C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D000893 - Anti-Inflammatory Agents D018501 - Antirheumatic Agents
2-Fluoroadenosine
2-Fluoroadenosine (2FA) is a nucleoside analogue. 2-Fluoroadenosine has antibacterial activity with IC50 value of 0.842 mM for Vibrio microvibrio[1].
1-(5-BROMOPYRIMIDINE-2-YL)PIPERDINE-3-CARBOXYLIC ACID
1-(4-methoxyphenyl)sulfonylpyrrolidine-2-carboxylic acid
Piperazine, 1-[4-(methylsulfonyl)-2-nitrophenyl]- (9CI)
9-(trifluoromethyl)-5,6,7,8-tetrahydropyrazolo[5,1-b]quinazoline-2-carboxylic acid
(2R,4S)-4-hydroxy-1-(4-methylphenyl)sulfonyl-pyrrolidine-2-carboxylate
N-(4-Bromo-2-methylphenyl)-3-methoxy-N-methylpropanamide
2-(5-FLUORO-1,3-DIOXO-1,3-DIHYDROISOINDOL-2-YL)BENZOICACID
ETHYL 3-BROMO-7-OXO-4,5,6,7-TETRAHYDRO-1H-INDOLE-2-CARBOXYLATE
7-nitro-4-(pyridin-2-ylmethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
5-(furan-2-yl)-3-p-tolyl-4,5-dihydro-1h-pyrazole-1-carbothioamide
2-AMINO-6-CHLORO-9-(BETA-D-2-DEOXYRIBOFURANOSYL)PURINE
1-(5-Bromopyrimidin-2-yl)piperidine-4-carboxylic acid
(E)-Methyl-2-(2-bromomethylphenyl)-2-Methoxyiminoacetate
6-(2-Bromo-ethyl)-1,3-dimethyl-1,6-dihydro-pyrrolo[3,4-d]pyrimidine-2,4-dione
7,10-Dihydro-8-nitro-7-oxo-1,10-phenanthroline-3-carboxylic acid
Ethyl 4-oxo-7-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxylate
Methyl 8-methyl-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-2-carboxylate
6-NITRO-4-(PYRIDINE-2-YLMETHYL)-1,4-BENZOXAZIN-3(4H)-ONE
1-pyridin-3-ylmethyl-pyrrolidin-3-ylamine trihydrochloride
Benzeneacetic acid,2-chloro-a-[[(1,1-dimethylethoxy)carbonyl]amino]-
[5-chloro-2-(cyclopropylmethylamino)phenyl]-phenylmethanone
5-(2-Fluorophenyl)-3-(3-nitrophenyl)-1,2,4-oxadiazole
1-[(4-chlorophenyl)methyl]-5-methylindole-2,3-dione
Methyl 7-fluoro-6-(phenylamino)-1H-benzo[d]imidazole-5-carboxylate
POTASSIUM [2-(BENZYLOXYCARBONYLAMINO)ETHYL] TRIFLUOROBORATE
(S)-6-(PROPYLAMINO)-5,6,7,8-TETRAHYDRONAPHTHALEN-1-OL HYDROBROMIDE
(3-Bromo-4-Methyl-phenyl)-carbamic acid tert-butyl ester
Ethyl 4-hydroxy-8-(trifluoromethyl)quinoline-3-carboxylate
Asenapine
N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AH - Diazepines, oxazepines, thiazepines and oxepines D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants An organic heterotetracyclic compound that is 2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole bearing methyl and chloro substituents at positions 2 and 5 respectively. C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Asenapine (Org 5222), an atypical antipsychotic, is an antagonist of serotonin receptors (pKi: 8.4-10.5), adrenoceptors (pKi: 8.9-9.5), dopamine receptors (pKi: 8.9-9.4) and histamine receptors (pKi: 8.2-9.0). Asenapine can be used in the research of schizophrenia and bipolar disorder[1][2].
Ethyl 5-fluoro-7-(methylsulphonyl)-1H-indole-2-carboxylate
1-propenyl-2,3-diMethyliMidazoliuM hexafluorophosphate
Nifuratel
G - Genito urinary system and sex hormones > G01 - Gynecological antiinfectives and antiseptics > G01A - Antiinfectives and antiseptics, excl. combinations with corticosteroids D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D000890 - Anti-Infective Agents > D000935 - Antifungal Agents D000890 - Anti-Infective Agents > D023303 - Oxazolidinones C254 - Anti-Infective Agent > C514 - Antifungal Agent
3-(2,6-Dichlorophenyl)-N-hydroxy-5-methylisoxazole-4-carboximidamide
(4-(N-(3-Methylbutanoyl)sulfamoyl)phenyl)boronic acid
dimethyl 2-[(2-chloroacetyl)amino]benzene-1,4-dicarboxylate
3-Quinolinecarboxylicacid, 4-hydroxy-7-(trifluoromethyl)-, ethyl ester
(S)-2-((TERT-BUTOXYCARBONYL)AMINO)-2-(4-CHLOROPHENYL)ACETIC ACID
(2R)-2-(3-chlorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid
7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylic acid
Ethyl 4-hydroxy-2-(trifluoromethyl)quinoline-3-carboxylate
Ethyl 5-(aminomethyl)-1,3,4-oxadiazole-2-carboxylate
7-benzoyl-2,4-dimethyl-2,4,7,8,9-pentazabicyclo[4.3.0]nona-8,10-diene-3,5-dione
1-(4-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)THIAZOL-5-YL)ETHANONE
3-{[(tert-Butoxycarbonyl)amino]methyl}-4-chlorobenzoic acid
2-[2-chloro-3-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]acetic acid
CARBAMIC ACID, N-(2-BROMO-4-METHYLPHENYL)-, 1,1-DIMETHYLETHYL ESTER
8-(4-fluorophenyl)-2-(trifluoromethyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine
3-(2,6-DICHLOROPHENYL)-5-METHYLISOXAZOLE-4-CARBOHYDRAZIDE
4-(4-(HYDROXYMETHYL)-2-METHOXY-5-NITROPHENOXY)BUTANOIC ACID
5-(1-methylcyclopropyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine-2-carboxylic acid
METHYL 3-METHYL-5-[4-(TRIFLUOROMETHYL)PHENYL]ISOXAZOLE-4-CARBOXYLATE
(2-CHLORO-4-MORPHOLINOTHIENO[3,2-D]PYRIMIDIN-6-YL)METHANOL
METHYL 4-(METHYLSULFONYL)-3-(1H-PYRROL-1-YL)THIOPHENE-2-CARBOXYLATE
ETHYL 5-(4-(TRIFLUOROMETHYL)PHENYL)ISOXAZOLE-3-CARBOXYLATE
Ethyl 4-hydroxy-6-(trifluoromethyl)quinoline-3-carboxylate
4-[(TETRAHYDRO-FURAN-2-YLMETHYL)-SULFAMOYL]-BENZOIC ACID
N-(4-Cyclopropyl-1-naphthalenyl)-2-formylhydrazinecarbothioamide
[3-(methylthio)-1-(3-phenyl-1,2,4-oxadiazol-5-yl)propyl]amine hydrochloride
6-Azido-6-deoxy-D-galactopyranose 1-(dihydrogen phosphate)
(R)-2-(2-Chloro-5-(trifluoromethyl)phenyl)pyrrolidine hydrochloride
3-(5-BROMO-2-METHOXY-PYRIDIN-3-YL)-ACRYLIC ACID ETHYL ESTER
2-Azido-1,3-dimethylimidazolinium hexafluorophosphate
5-(3-TRIFLUOROMETHYLPHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID ETHYL ESTER
2-{[(4-Methoxy-3-Methyl-2-Pyridinyl)Methyl]Sulfanyl}-1H-Benzimidazole
(4-Methoxy-3-(pyrrolidin-1-ylsulfonyl)phenyl)boronic acid
(2-Methyl-4-(morpholinosulfonyl)phenyl)boronic acid
2,5-Pyrrolidinedicarboxylic acid, 1-(phenylmethyl)-, hydrochloride (9CI)
1-[2-(4-CHLOROPHENYL)-7-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-6-YL]ETHAN-1-ONE
2′-Deoxy-2′-fluoroguanosine
2′-Deoxy-2′-fluoroguanosine, a nucleoside analog, is a potent inhibitor of influenza virus strains, with an EC90 of <0.35 μM for influenza virus A and B strains. 2′-Deoxy-2′-fluoroguanosine significantly inhibits replication of influenza virus in the upper respiratory tract, resulting in amelioration of fever and nasal inflammation[1][2].
N-(2-Aminoethyl)-5-chloroisoquinoline-8-sulfonamide
CKI-7 free base is a potent and ATP-competitive casein kinase 1 (CK1) inhibitor with an IC50 of 6 μM and a Ki of 8.5 μM. CKI-7 free base is a selective Cdc7 kinase inhibitor. CKI-7 free base also inhibits SGK, ribosomal S6 kinase-1 (S6K1) and mitogen- and stress-activated protein kinase-1 (MSK1). CKI-7 free base has a much weaker effect on casein kinase II and other protein kinases[1][2][3][4].
9-Chloro-2-(2-furyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-imine
CGS 15943 is an orally bioavailable non-xanthine Adenosine Receptor antagonist. Its Ki for human A1, A2A, A2B, and A3 Adenosine Receptors are 3.5, 4.2, 16, and 50 nM in transfected CHO cells, respectively. [1][2].
2-(6-Amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
D000970 - Antineoplastic Agents
5-BENZOXAZOLEACETIC ACID, 2-(4-FLUOROPHENYL)-alpha-METHYL-
5-(6-Amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
N-(2-furanylmethyl)-3-methyl-7,8-dihydro-6H-cyclopenta[4,5]thieno[1,2-c]pyrimidin-1-amine
5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide
3-[2-(3-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one
3-[2-(4-Methylphenoxy)ethyl]-1,3-benzothiazol-2-one
3-Nitro-4-(2-oxo-pyrrolidin-1-yl)-benzenesulfonamide
Cyanidin(1-)
An organic anion obtained by selective deprotonation of the 3- and 5-hydroxy groups of cyanidin(1+).
(1S,2R)-1-(1H-indol-3-yl)-3-(phosphonatooxy)propane-1,2-diol
2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-olate luteolin-7-olate(1-)
2-Amino-4,5-dihydroxy-6-oxo-7-(phosphooxy)heptanoate
gentisate 5-O-beta-D-xylopyranoside
D000893 - Anti-Inflammatory Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D012459 - Salicylates
(Z)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-3-oxoprop-1-en-1-olate
5-amino-4-chloro-2-(2-hydroxymuconoyl)pyridazin-3(2H)-one
4-dihydro-9-hydroxy-1-methyl-10-oxo-3-H-naptho-[2,3-c]-pyran-3-(S)-acetic acid
3,5,6,7-Tetrahydroxy-2-(4-hydroxyphenyl)chromenium
(2S,4R,5R,6R)-6-(4-amino-2-oxopyrimidin-1-yl)-4,5-dihydroxy-3-oxooxane-2-carboxylic acid
2-(6-amino-2-fluoro-7H-purin-8-yl)oxane-3,4,5-triol
N(1)-(5-phospho-D-ribosyl)glycinamide(1-)
Conjugate base of N(1)-(5-phospho-D-ribosyl)glycinamide. COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Scutellarein(1-)
A flavonoid oxoanion that is the conjugate base of scutellarein, obtained by selective deprotonation of the 7-hydroxy group. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
4-butyl-3-(4-chloro-1,5-dimethyl-3-pyrazolyl)-1H-1,2,4-triazole-5-thione
N-(1-propyl-5-benzimidazolyl)-2-thiophenecarboxamide
3-[4-(2-methylphenyl)-5-sulfanylidene-1H-1,2,4-triazol-3-yl]-1H-pyridazin-6-one
N-(3-bicyclo[2.2.1]heptanyl)-4-chlorobenzenesulfonamide
7-Chloro-2-methyl-3-(pyridin-4-ylmethyl)quinazolin-4-one
N-(5-amino-1-phenyl-1,2,4-triazol-3-yl)-2-thiophenecarboxamide
N-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]-2-thiophenecarboxamide
1-Tert-butyl-3-[[(2-chlorophenyl)-oxomethyl]amino]thiourea
3-(3-Pyridinylmethylthio)-6-thiophen-2-ylpyridazine
2-(4-Chloro-2-methylphenoxy)acetic acid [2-(ethylamino)-2-oxoethyl] ester
(3-Chloro-phenyl)-(6,7-dihydro-5H-cyclopenta[d][1,2,4]triazolo[1,5-a]pyrimidin-8-yl)-amine
rubrofusarin B(1-)
A phenolate anion obtained by deprotonation of the 5-hydroxy group of rubrofusarin B. It is the major microspecies at pH 7.3.
6-chloro-4-hydroxy-3-(phenylmethyl)-1H-quinolin-2-one
(2R,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol
(3R)-5-(6-amino-2-chloro-9-purinyl)-2-(hydroxymethyl)-3-oxolanol
Aureusidin-6-olate
An organic anion that is the conjugate base of aureusidin, arising from selective deprotonation of the hydroxy group at position 6 of the benzofuran moiety; major species at pH 7.3.
6beta-[(S)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid
4-[[4-[Nitroso(oxo)methyl]phenyl]hydrazo]benzoic acid
2,3-dihydrobiochanin A(1-)
Conjugate base of 2,3-dihydrobiochanin A arising from selective deprotonation of the 7-hydroxy group.
(5R)-6-(1-hydroxyethyl)-7-oxo-3-[(2R)-tetrahydrofuran-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-(oxolan-2-yl)-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
3-Methyl-4-thiophen-2-yl-2,4,4a,6,7,8-hexahydropyrazolo[3,4-b]quinolin-5-one
(2xi)-3-deoxy-7-O-phosphonato-beta-D-threo-hept-6-ulopyranosonate
(2E)-2-(5-fluoro-2-oxo-1H-indol-3-ylidene)-2-(4-methyl-1,3-thiazol-2-yl)acetonitrile
(5R,6S)-6-[(1S)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
6alpha-[(R)-1-hydroxyethyl]-2-[(R)-tetrahydrofuran-2-yl]pen-2-em-3-carboxylic acid
(S,S)-asenapine
A 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have S configuration.
(1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate(2-)
Dianion of (1S,2R)-1-C-(indol-3-yl)glycerol 3-phosphate arising from deprotonation of both phosphate OH groups.
2-hydroxygenistein(1-)
A flavonoid oxoanion obtained by deprotonation of the 7-hydroxy group of 2-hydroxygenistein. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).
(R,R)-asenapine
A 5-chloro-2-methyl-2,3,3a,12b-tetrahydrodibenzo[2,3:6,7]oxepino[4,5-c]pyrrole in which both of the stereocentres have R configuration.
1-C-(indol-3-yl)glycerol 3-phosphate(2-)
An organophosphate oxoanion resulting the from removal of two protons from the phosphate group of 1-C-(indol-3-yl)glycerol 3-phosphate.
luteolin-7-olate
A flavonoid oxoanion that is the conjugate base of luteolin, arising from selective deprotonation of the 7-hydroxy group.
4-nitrophenyl alpha-L-fucoside
An alpha-L-fucoside that is alpha-L-fucopyranose in which the anomeric hydroxy hydrogen is replaced by a 4-nitrophenyl group.
catechol beta-D-glucuronide(1-)
A carbohydrate acid derivative anion resulting from the removal of a proton from the carboxy group of catechol beta-D-glucuronide.
7-Phospho-2-dehydro-3-deoxy-D-arabino-heptonate
An organophosphate oxoanion arising from deprotonation of the carboxy and phosphate OH groups of 7-phospho-2-dehydro-3-deoxy-D-arabino-heptonic acid; major species at pH 7.3.
4'-C-Azidouridine
4'-C-azidouridine (4'-Azidouridine) is a uridine analogue. Uridine has potential antiepileptic effects, and its analogs can be used to study anticonvulsant and anxiolytic activities, as well as to develop new antihypertensive agents[1]. 4'-C-Azidouridine is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
Nucleoside-Analog-2
Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (HCV) replication. Nucleoside-Analog-2 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
SIRT7 inhibitor 97491
SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway.[1].
